Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haploidentical NK cell therapy (Seoul National University Hospital)
- Development stage
- Unknown
- Lead developer
- Seoul National University Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Haploidentical NK cell therapy is an adoptive cellular immunotherapy developed by Seoul National University Hospital for the treatment of refractory or relapsed malignant melanoma. The therapy involves the infusion of ex vivo expanded natural killer (NK) cells derived from a haploidentical (partially HLA-matched) donor. This approach leverages the 'missing-self' hypothesis, where the mismatch between the donor's killer cell immunoglobulin-like receptors (KIRs) and the recipient's HLA ligands prevents the inhibition of NK cells, thereby enhancing their ability to recognize and lyse tumor cells. The cells are typically processed via CD3+ depletion to minimize the risk of graft-versus-host disease (GvHD) before expansion and infusion.
- Other names
- Haploidentical natural killer cell infusionAllogeneic NK cell therapyHaploidentical NK cell
Beyond the preview
Go deeper on Haploidentical NK cell therapy (Seoul National University Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haploidentical NK cell therapy (Seoul National University Hospital).